Pierrel S.p.A

What Pierrel S.p.A does

Pierrel S.p.A. is an Italian pharmaceutical company founded in 1948 and headquartered in Capua, Italy, specializing in the production, development, registration, and licensing of dental anesthetics and complementary medical devices for oral health. The company operates a manufacturing facility authorized by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and other major global regulatory bodies for the production of injectable sterile drugs. Its product portfolio is organized into three functional categories: Anesthesia (proprietary branded dental anesthetics including Ubisestin, Xylestesin, Mepivastesin, and Orabloc, plus acquired 3M needles and syringes), Prevention (screening products for oral cavity pathologies), and Regeneration (medical devices for oral mucosa regeneration in cases of gingivitis and periodontitis, including Ubigel Inperio). Pierrel is publicly listed on Euronext Milan.

The company's business model rests on proprietary branded pharmaceutical products distributed through an international network of distributors and dealers, supplemented by direct B2B engagement with dental practices and presence at industry trade shows such as Expodental Meeting (Italy) and IDS (Cologne). Customers are primarily dental professionals (general dentists and specialists) and distribution partners across 36 countries, with investors as a secondary audience served through investor relations disclosures. Revenue is generated from pharmaceutical product sales and licensing/registration activities across multiple jurisdictions. Pricing, contract terms, and per-product unit economics are not publicly disclosed.

In 2023 Pierrel executed a transformative capital raise and acquisition: a €70 million post-IPO capital increase in June 2023 funded the August 2023 acquisition of 3M Company's global dental anesthetic portfolio for $70 million, transferring 58 active marketing authorizations across 36 countries, established brands, commercial agreements, and complementary medical devices. Management has guided that sales are expected to double in the next fiscal year with significant further increases thereafter, and that production capacity at the Capua facility will triple as German 3M production is onshored to Italy. Headcount is reported at 501-1,000 employees as of the last disclosure.

Name

Pierrel S.p.A

Legal name

Pierrel S.p.A.

Website

https://pierrelgroup.com

Company type

Public

Founded year

1948

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Pierrel S.p.A. is an Italian pharmaceutical company that develops, manufactures, and licenses proprietary dental anesthetics and complementary medical devices for oral health, serving dental professionals and distributor networks across 36 countries from an EMA- and FDA-authorized facility in Capua.

Ownership category

akta.pro rank

Product category

Dental Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Dental Equipment and Supplies Manufacturing (339114), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Dental Equipment & Supplies (3843), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Dental Implants & Prosthodontic Components (Implants/Abutments/Prosthetics) (HLAHAEAE)

Keywords

• Dental anesthetics
• Injectable pharmaceuticals
• Oral care devices
• Periodontal treatment
• Pharmaceutical manufacturing

Headquarters

HQ city

Capua

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pierrel generates revenue primarily from the sale of its own branded dental anesthetic products and medical devices. Following the 2023 acquisition of 3M's dental anesthetic assets, the company significantly expanded its product portfolio and geographic reach, with 58 commercial authorizations in 36 countries, and projects doubled sales in the near term.
2. Licensing and Registration: The company derives revenue from licensing its pharmaceutical products and managing regulatory registrations across international markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Pierrel S.p.A. develops, manufactures, registers, and commercializes branded dental anesthetics (Ubisestin, Xylestesin, Mepivastesin, Orabloc) and complementary medical devices such as Ubigel Inperio for periodontal disease, dental needles, and syringes. Operations are centered on its EMA- and FDA-authorized injectable sterile manufacturing facility in Capua, Italy, with the product portfolio expanded in 2023 through the acquisition of 3M's dental anesthetic assets.

Product overview

Pierrel S.p.A. is a pharmaceutical company offering a portfolio of dental anesthetics and complementary medical devices for oral health. The product portfolio spans three main categories: Anestesia (dental anesthesia drugs including Ubisestin, Xylestesin, Mepivastesin, and Orabloc, plus complementary medical devices), Prevenzione (screening products for oral cavity pathologies), and Rigenerazione (regeneration products for oral mucosa in cases of gingivitis and periodontitis, such as Ubigel Inperio). The company also acquired 3M's dental anesthetic portfolio (58 marketing authorizations in 36 countries) including needles and dental syringes for pain management. Products are authorized by EMA, FDA, and major global regulatory bodies, with manufacturing based in Capua, Italy.

Differentiator

Problem solved

Functional benefit

Brands

• Ubisestin™: Dental anesthetic product in Pierrel's portfolio
• Xylestesin™
• Mepivastesin™
• Orabloc
• Ubigel Inperio

Products and services

• Ubisestin Dental anesthetic product commercialized under Pierrel's own brand across international markets, part of the company's multi-molecule anesthesia portfolio for dental professionals.
• Xylestesin Dental anesthetic brand in Pierrel's own-brand portfolio, commercialized across multiple international markets for use in dental procedures.
• Mepivastesin Dental anesthetic brand in Pierrel's portfolio; Mepivacaine-based formulation approved for use in Taiwan and other markets.
• Orabloc Pierrel's own-brand dental anesthetic product, with marketing authorizations secured across multiple countries including Greece, Saudi Arabia, Uzbekistan, Algeria, Ecuador, and Taiwan.
• Ubigel Inperio Medical device for the treatment of periodontal disease (periodontitis), supporting oral mucosa regeneration in patients with gingivitis and periodontitis.
• Complementary Anesthesia Devices (Dental Needles and Syringes) Dental needles and syringes for pain management, included in Pierrel's anesthesia product offering following the acquisition of 3M's dental anesthetic portfolio.
• Oral Prevention Products Products for screening of oral cavity pathologies, supporting early detection and preventive oral healthcare in dental practice.
• Oral Regeneration Products Products for oral mucosa regeneration in cases of gingivitis and periodontitis, supporting tissue healing and oral health recovery, including the Ubigel Inperio medical device.

Quantifiable outcome

• Production capacity expected to triple at the Capua manufacturing facility following the 3M asset transfer.
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• 3M CompanycoreStrategic or Co-development Partner · 1 August 2023In August 2023, Pierrel completed the acquisition of strategic dental anesthetic assets from 3M Company for $70 million. The acquisition included 58 active marketing authorizations in 36 countries, commercial agreements, brands, and licenses for dental anesthetics, as well as medical devices such as dental needles and syringes. The transaction enabled Pierrel to onshore pharmaceutical productions from Germany to Italy, implement a substantial R&D project, further internationalize its presence, and expand its distribution network to include new prestigious markets such as Japan and Hong Kong. The deal was funded by a successful capital increase, with the market recognizing the merit of the operation.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Septodont: Septodont is a privately held French pharmaceutical manufacturer specializing in dental anesthetics (e.g., articaine, lidocaine, mepivacaine) and endodontic products. It is the most direct competitor to Pierrel in dental local anesthesia and shares Pierrel's pharma-grade, branded, regulatory-driven model.
• Ultradent Products: Ultradent is a US-based manufacturer of dental anesthetics, endodontic materials, and preventive/restorative dental products. It competes directly with Pierrel in branded dental anesthetics and shares a similar model of selling proprietary pharmaceutical and device products through dental distributors worldwide.
• Novocol Pharma: Novocol Pharma (a Septodont subsidiary) is a Canadian contract manufacturer specializing in injectable dental anesthetics. It is a close functional comparable to Pierrel's Capua sterile injectable plant and shares Pierrel's pharma-grade, regulatory-driven manufacturing model.

Broad incumbents

• Dentsply Sirona: Dentsply Sirona is the largest global manufacturer of professional dental equipment, consumables, and technologies. While broader in scope, it sells into the same dental professional channel Pierrel targets and historically competed in dental anesthetics and anesthetics-adjacent consumables before divesting parts of that portfolio.
• 3M Oral Care (Solventum): 3M's former Oral Care business (now part of Solventum following the 2024 spin-off) sold the dental anesthetic assets Pierrel acquired in 2023. It remains a comparable reference point because of the brands, contracts, and registrations transferred to Pierrel, and continues to operate broadly in dental and oral care products.
• Henry Schein: Henry Schein is the world's largest distributor of dental supplies, equipment, and pharmaceuticals, including dental anesthetics. Pierrel's products flow through comparable distribution channels, and Henry Schein is a key account-level benchmark for Pierrel's distributor-and-dealer go-to-market model.
• Patterson Companies: Patterson is a leading North American dental and animal health distributor, supplying dental practices with anesthetics, consumables, and equipment. It is relevant as both a potential channel partner for Pierrel and a comparable dental-distribution scale benchmark.

Emerging players

• Young Innovations: Young Innovations manufactures and distributes preventive and restorative dental products, including anesthetic-related consumables sold to dental professionals. It is a smaller, more focused peer with overlapping customer and channel dynamics to Pierrel.

Others

• Colgate-Palmolive (Oral Care): Colgate-Palmolive operates a major consumer oral-care franchise but does not directly compete in dental anesthetics. It is a useful adjacent benchmark for Pierrel's longer-term ambition to extend into prevention and regeneration products within the broader oral health category.

Regional players

• Benco Dental: Benco Dental is the largest privately owned dental distributor in the United States, supplying anesthetics, equipment, and consumables to dental practices. It is comparable as a dental distribution channel partner, though its geographic focus on North America differentiates it from Pierrel's more international footprint.

Market position

Strengths1 record

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pierrel-spa
• Facebookfacebook.com/PierrelSpa

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pierrel S.p.A